Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Angular momentum generation in nuclear fission.

Nature·2021
Same author

[Antithrombotic treatment in acute coronary syndrome and atrial fibrillation].

Herz·2019
Same author

[Acute coronary syndrome : Prevention].

Herz·2019
Same author

The German CPU registry: Comparison of smokers and nonsmokers.

Herz·2018
Same author

Cecal Resection with Bipolar Sealing Devices in a Rat Model.

Journal of investigative surgery : the official journal of the Academy of Surgical Research·2018
Same author

[Hemorrhage under direct oral anticoagulants : Occurrence and treatment in intensive care patients].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2018

相关实验视频

Updated: May 14, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

在缺血性心肌再注射期间使用C1-酶抑制剂:与剂量相关的有益与有害影响.

G Horstick1, O Berg, A Heimann

  • 12nd Medical Clinic, Institute for Neurosurgical Pathophysiology, Johannes Gutenberg University, Mainz, Germany.

Circulation
|December 19, 2001
PubMed
概括

当C1-酶抑制剂 (C1-INH) 用于低剂量时,可以在再注射期间保护心脏免受损伤. 较高剂量的C1-INH会引起危险的副作用,这凸显了正确剂量的重要性.

更多相关视频

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

相关实验视频

Last Updated: May 14, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

科学领域:

  • 心血管研究研究心血管研究
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 补充激活会在再注射过程中加剧心肌损伤.
  • 在实验模型中,C1-酶抑制剂 (C1-INH) 显示出心脏保护作用.
  • 对于新生儿的C1-INH安全性存在担忧,需要对剂量进行评估.

研究的目的:

  • 调查C1-INH对心肌再注射损伤的剂量依赖性影响.
  • 为了确定C1-INH用于心脏保护的最佳剂量.
  • 评估C1-INH在不同剂量的安全性.

主要方法:

  • 心肌缺血-再输血的猪模型 (60分钟的闭塞,120分钟的再输血).
  • 在再注血之前,静脉注射C1-INH (40, 100, 200 IU/kg)
  • 评估心肌损伤,补充激活 (C3a,C5a) 和心脏生物标志物 (肌酸激酶,热素T).

主要成果:

  • 40 IU/kg的C1-INH显著降低了心肌缩 (44.1%vs76.7%),并抑制了C3a/C5a生成.
  • 在40 IU/kg的剂量下观察到较低的肌酸激酶和素T水平.
  • 100 IU/kg C1-INH没有看到心脏保护; 200 IU/kg诱导严重的副作用和凝血障碍.

结论:

  • 正确的C1-INH剂量可以显著保护心肌损伤.
  • 100 IU/kg或更高的剂量与有害的副作用有关,可能是由于促血凝的作用.
  • 剂量对于C1-INH在治疗心肌缺血-再输液损伤中的安全有效使用至关重要.